Hematology CAR-T deals reach this total value at Phase 1

CAR-T cell therapy in hematologic malignancies commands premium deal terms even at Phase 1, with $247M median upfronts. Six approved CAR-T products generating $5B+ combined annual revenue have validated the modality. Next-generation targets (GPRC5D, CD70), allogeneic platforms, and in-vivo CAR-T approaches are driving the next wave of high-value licensing deals.

Based on analysis of 600+ biopharma licensing deals from 2020-2026